Ocular Therapeutix
Healthcare & Life Sci
Company overview
Ocular Therapeutix is a biopharmaceutical company based in Bedford. It develops, manufactures, and sells therapies for eye diseases using its own hydrogel platform technology. Its lead product, DEXTENZA, is FDA-approved for ocular inflammation and pain after eye surgery. AXPAXLI, a treatment for wet AMD, is in Phase 3 trials.
Ocular Therapeutix was founded in 2006. It trades publicly on the NASDAQ stock exchange under the ticker OCUL. That means investors can buy and sell shares in the company on the open market. Ocular Therapeutix is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Bedford, United States